The Possibility of Correcting Anxiety Symptoms in Cardiac Patients in Primary Care Settings: Results of the Therapeutic Part of a Russian Multicenter Study COMETA

Purpose: to assess efficacy of correction of anxiety states by anxiolytic drug fabomotizole in ambulatory patients with arterial hypertension (AH) and / or ischemic heart disease (IHD).

Materials and methods. In the framework of multicenter cross-sectional study with participation of patients aged ≥55 years with verified AH / IHD we conducted the therapeutic part of the COMETA program in which we included patients with comorbid anxiety state (≥11 points on the Hospital Anxiety and Depression Scale Anxiety [HADS-A] and clinically expressed anxiety state) without clinically expressed depressive symptoms (<11 points on the HADS-Depression). Participants were randomized into main and control groups. Patients in the main group in addition to therapy prescribed because of AH / IHD were given a recommendation to take fabomotizole (10 mg thrice a day), patients of control group received standard therapy. Efficacy of therapy was evaluated by HADS and visual analog scale after 6 and 12 weeks of observation.

Results. We included 182 and 104 in the main and control groups, respectively. Most patients in main and control groups had AH (97.3 and 95.2 %, respectively, about one third had IHD (36.8 and 30.8 %, respectively). Social-demographic, clinical characteristics, and recommended for AH / IHD treatment of participants of both groups were similar. Portion of patients with complete reduction of anxiety symptoms (<8 points on HADS-A) was significantly higher already after 6 weeks of fabomotizole therapy (37.9 and 19.2 %, respectively, p<0.001). Analogous picture was noted by the end of observation (66.9 and 32 %, respectively; p<0.001). Mean estimate of chronic psychoemotional stress in the main group decreased by 25 % after 6 weeks (from 6.45±2.20 to 5.05±1.96 points; р<0.001) and by 40 % after 12 weeks (from 6.45±2.20 to 3.98±1.99 points; р<0.001). In the control group it also decreased but degree of lowering was 2 times less than in the main group (11.1 % vs. 25 % after 6 weeks, р=0.016; and 20 % vs. 40 % after 12 weeks, р<0.001, respectively).

Conclusion. The use of fabomotizole by patients with AH / IHD provided improvement of psychological status (reduction of anxiety symptoms and lowering of the level of chronic psychoemotional stress).

1. Starostina E.G. Generalized anxiety disorder and anxiety symptoms in general medical practice. Russian Medical Journal. 2004;12(22):1277–83.

2. Krasnov V.N. Mental disorders in general medical practice. Russian Medical Journal. 2002;10(25):1187‒1191.

3. Chazov E.I., Oganov R.G., Pogosova N.V., Shal’nova S.A., Deev A.D. Clinico-Epidemiological Program of the Study of Depression in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease (COORDINATA): results of multicenter prospective. Kardiologiia. 2007;47(3):28–37.

4. Starostina E.G. Generalized anxiety disorder and anxiety symptoms in general medical practice. Russian Medical Journal. 2004;12(22):1277–83.

5. Pogosova N.V., Boytsov S.A., Oganov R.G., Yufereva Yu.M., Kostyuk G.P., Kursakov A.A. et al. Clinical-Epidemiological Program of Studying Psychosocial Risk Factors in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease: First Results of a Multicenter Study in Russia. Kardiologiia. 2018;58(9):47–58. DOI: 10.18087/cardio.2018.9.10171

6. Chazov E.I., Oganov R.G., Pogosova N.V., Shal’nova S.A., Deev A.D. Clinico-Epidemiological Program of the Study of Depression in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease (COORDINATA): results of multicenter prospective. Kardiologiia. 2007;47(3):28–37.

7. Grace SL, Abbey SE, Irvine J, Shnek ZM, Stewart DE. Prospective Examination of Anxiety Persistence and Its Relationship to Cardiac Symptoms and Recurrent Cardiac Events. Psychotherapy and Psychosomatics. 2004;73(6):344–52. DOI: 10.1159/000080387

8. Pogosova N.V., Boytsov S.A., Oganov R.G., Yufereva Yu.M., Kostyuk G.P., Kursakov A.A. et al. Clinical-Epidemiological Program of Studying Psychosocial Risk Factors in Cardiological Practice in Patients With Arterial Hypertension and Ischemic Heart Disease: First Results of a Multicenter Study in Russia. Kardiologiia. 2018;58(9):47–58. DOI: 10.18087/cardio.2018.9.10171

9. Hanssen TA, Nordrehaug JE, Eide GE, Bjelland I, Rokne B. Anxiety and depression after acute myocardial infarction: an 18-month follow-up study with repeated measures and comparison with a reference population. European Journal of Cardiovascular Prevention & Rehabilitation. 2009;16(6):651–9. DOI: 10.1097/HJR.0b013e32832e4206

10. Grace SL, Abbey SE, Irvine J, Shnek ZM, Stewart DE. Prospective Examination of Anxiety Persistence and Its Relationship to Cardiac Symptoms and Recurrent Cardiac Events. Psychotherapy and Psychosomatics. 2004;73(6):344–52. DOI: 10.1159/000080387

11. Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Höfer S et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. European Journal of Preventive Cardiology. 2015;22(10):1290–306. DOI: 10.1177/2047487314543075

12. Hanssen TA, Nordrehaug JE, Eide GE, Bjelland I, Rokne B. Anxiety and depression after acute myocardial infarction: an 18-month follow-up study with repeated measures and comparison with a reference population. European Journal of Cardiovascular Prevention & Rehabilitation. 2009;16(6):651–9. DOI: 10.1097/HJR.0b013e32832e4206

13. Pogosova N.V., Koltunov I.E., Yufereva Yu.M. Anxiety disorders in cardiology practice: State of the problem. Russian Journal of Cardiology. 2010;15(5):98–102.

14. Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Höfer S et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. European Journal of Preventive Cardiology. 2015;22(10):1290–306. DOI: 10.1177/2047487314543075

15. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and Risk of Incident Coronary Heart Disease. Journal of the American College of Cardiology. 2010;56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034

16. Pogosova N.V., Koltunov I.E., Yufereva Yu.M. Anxiety disorders in cardiology practice: State of the problem. Russian Journal of Cardiology. 2010;15(5):98–102.

17. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. American Heart Journal. 2015;170(6):1105–15. DOI: 10.1016/j.ahj.2015.09.013

18. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and Risk of Incident Coronary Heart Disease. Journal of the American College of Cardiology. 2010;56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034

19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67(6):361–70. PMID: 6880820

20. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. American Heart Journal. 2015;170(6):1105–15. DOI: 10.1016/j.ahj.2015.09.013

21. Celano CM, Daunis DJ, Lokko HN, Campbell KA, Huffman JC. Anxiety Disorders and Cardiovascular Disease. Current Psychiatry Reports. 2016;18(11):101. DOI: 10.1007/s11920-016-0739-5

22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67(6):361–70. PMID: 6880820

23. Alexandrovski Y.A., Neznanov N.G. Psychiatry. National guideline, 2nd edition. - M.: GEOTAR-Media, 2018. - 1008 p.

24. Celano CM, Daunis DJ, Lokko HN, Campbell KA, Huffman JC. Anxiety Disorders and Cardiovascular Disease. Current Psychiatry Reports. 2016;18(11):101. DOI: 10.1007/s11920-016-0739-5

25. Mosolov S.N. Biological methods of mental disorders management (evidence-based medicine to clinical practice). Gorodnichev A.V. Current trends in anxiety disorders management: from scientific data to clinical guidelines. - P.643-668. -M.: Socio‒political thought; 1080 p. ISBN 978-5-91579-075-8

26. Alexandrovski Y.A., Neznanov N.G. Psychiatry. National guideline, 2nd edition. - M.: GEOTAR-Media, 2018. - 1008 p.

27. Seredenin S.B., Voronin M.V. Neuroreceptor mechanisms involved in the action of afobazole. Experimental and clinical pharmacology. 2009;72(1):3–11.

28. Mosolov S.N. Biological methods of mental disorders management (evidence-based medicine to clinical practice). Gorodnichev A.V. Current trends in anxiety disorders management: from scientific data to clinical guidelines. - P.643-668. -M.: Socio‒political thought; 1080 p. ISBN 978-5-91579-075-8

29. Tatarski B.A., Biserova I.N. Afobazole use in paroxysmal atrial fibrillation management. Russian Medical Journal. 2007;15(9):760‒766.

30. Seredenin S.B., Voronin M.V. Neuroreceptor mechanisms involved in the action of afobazole. Experimental and clinical pharmacology. 2009;72(1):3–11.

31. Tatarski B.A., Biserova I.N. Afobazole use in paroxysmal atrial fibrillation management. Russian Medical Journal. 2007;15(9):760‒766.